INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/18/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/17/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/16/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/15/2025
|
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of the securities laws.
- 04/15/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
- 04/14/2025
|
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm.
- 04/13/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
- 04/08/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 04/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/06/2025
|
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
- SAN DIEGO and NEW HAVEN, Conn. , April 5, 2025 /PRNewswire/ -- Biohaven Ltd.
- 04/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
- 04/04/2025
|
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
- Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
- 04/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/01/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/31/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/30/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/26/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/23/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/21/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bronstein, Gewirtz & Grossman, LLC (BHVN) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/20/2025
|
Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd.
- NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/19/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Shareholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/19/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/19/2025
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Biohaven Ltd. (BHVN) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/18/2025
|
Biohaven Ltd. (BHVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/18/2025
|
Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd.
- NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/17/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/17/2025
|
BHVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Biohaven Ltd. investment
- NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/17/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Shareholders to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/17/2025
|
Levi & Korsinsky Reminds Biohaven Ltd. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BHVN
- NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/16/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Shareholders to Connect
- NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/16/2025
|
Investors who lost money on Biohaven Ltd. should contact Levi & Korsinsky about an ongoing investigation - BHVN
- NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/15/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/15/2025
|
ATTENTION BHVN SHAREHOLDERS: Investors who lost money on Biohaven Ltd. are urged to contact Levi & Korsinsky about an ongoing investigation
- NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/14/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Investors to Connect
- NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/14/2025
|
BHVN STOCK ALERT: Levi & Korsinsky Notifies Biohaven Ltd. Investors of an Ongoing Investigation
- NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/13/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE:BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/13/2025
|
Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/13/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Stockholders to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/13/2025
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Biohaven Ltd. (BHVN) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/12/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Investors to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/12/2025
|
Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd.
- NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/11/2025
|
Biohaven Ltd. (BHVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/11/2025
|
ATTENTION Biohaven Ltd. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/10/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Investors to Connect
- NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/10/2025
|
Biohaven Ltd. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BHVN
- NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/09/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/09/2025
|
Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd.
- NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/07/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Investors to Inquire about Securities Investigation
- NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/07/2025
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Biohaven Ltd. (BHVN) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/06/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Investors to Reach Out
- NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/06/2025
|
Did Biohaven Ltd. Mislead Investors?
- NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/05/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Stockholders to Reach Out
- NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/05/2025
|
Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd.
- NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
- NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/04/2025
|
Biohaven Ltd. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BHVN
- NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
- 03/04/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Stockholders to Connect
- NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN).
- 03/04/2025
|
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
- On Monday, Biohaven Ltd. BHVN highlighted data from BHV-1300, showing rapid and deep reductions in total IgG for the potential treatment of autoimmune disease.
- 03/03/2025
|
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
- Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn-targeting competition. Up to 84% reduction of total IgG was observed with a median reduction of 80% after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.
- 03/03/2025
|
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
- Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million.
- 03/03/2025
|
Biohaven's Exciting Year Of Catalysts
- Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth.
- 02/28/2025
|
Why Biohaven Stock Triumphed on Tuesday
- News of a big and important regulator's move was the electricity that powered Biohaven (BHVN 11.19%) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is now significantly closer to potential approval, and many are feeling bullish about the company.
- 02/11/2025
|
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
- Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied for bipolar disorder and MDD, with data expected in 2025. The global major depressive disorder treatment market is expected to reach $14.96 billion by 2032.
- 02/11/2025
|
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the primary and secondary outcome measures at the 3-year endpoint in a real-world evidence (RWE) study.
- 02/11/2025
|
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
- Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDETM (molecular degraders of extracellular proteins) platform and the next generation TRAPTM (targeted removal of aberrant protein) degraders, including: IgA Nephropathy (IgAN) program: First-in-human dosing with BHV-1400, a next generation TRAP degrader, achieved rapid, deep, and selective lowering of only aberrant galactose-deficient IgA1 (Gd-IgA1), the antibody causing IgA nephropathy, while sparing normal IgA.
- 01/13/2025
|
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- NEW HAVEN, Conn. , Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd.
- 01/07/2025
|
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
- On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion channel programs.
- 12/17/2024
|
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
- BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within hours of each weekly dose administration, and pharmacodynamic effects were sustained relative to baseline over the four-week period.
- 12/16/2024
|
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
- Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing Phase 2 and 3 clinical studies , demonstrating excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as somnolence and cognitive/mood disturbances. Qualitative assessment of online social media platforms and forums provided a unique perspective of the unmet needs that people with epilepsy are vocalizing outside of the clinical setting, including the negative impact that ASM associated adverse events have on their quality of life.
- 12/06/2024
|
Biohaven's Revenue Path: SCA And Obesity Therapies
- Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials.
- 11/29/2024
|
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
- On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
- 11/25/2024
|
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
- 11/25/2024
|
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
- Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care.
- 11/25/2024
|
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
- In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care (SOC) group. Efficacy signals were observed in clinically relevant and biomarker-defined subgroups including those related to age, ambulatory status, background therapy, and baseline myostatin level.
- 11/25/2024
|
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
- Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA) Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes Statistically significant superiority achieved on 9 consecutive, prespecified primary and secondary endpoints Both the study protocol and statistical analysis plan were submitted to, and reviewed by, the U.S. Food and Drug Administration (FDA) prior to topline data analysis Study designed in discussion with the FDA and utilized Phase 3 data and an external control of matched, untreated SCA subjects from the U.S. Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) in accordance with the FDA's Guidance on Real-World Evidence (RWE) of effectiveness CRC-SCA external control included contemporaneous natural history data gathered from 2010-2024 Planned New Drug Application (NDA) re-submission in 4Q 2024 Completed clarification meeting with CHMP Rapporteurs in 4Q 2024 and MAA documents are being updated to include the new positive BHV4157-206-RWE study data with broader indication to include all SCA genotypes Taldefgrobep alfa, a myostatin-inhibitor, Phase 3 topline data in spinal muscular atrophy (SMA) in 4Q 2024 and Phase 2 trial protocol in obesity expected in 4Q 2024 Advancing extracellular Molecular Degrader of Extracellular Protein (MoDE) programs 3 additional investigational agents expected to enter Phase 1 studies in the next quarter Anticipate Phase 1 update for BHV-1300, including subcutaneous formulation, before year-end Broad progress with TRPM3 antagonist Initiated pivotal Phase 2 trial evaluating BHV-2100, a TRPM3 antagonist, in the acute treatment of migraine Initiated separate proof of concept study with BHV-2100 in neuropathic pain Patient enrollment continues across 5 Phase 2/3 trials with Kv7 activator, BHV-7000, in epilepsy and mood disorders (bipolar and major depressive disorder (MDD)) with potential for multiple data readouts in 2025 Continued progress with antibody drug conjugate (ADC) portfolio BHV-1510 currently dosing cancer patients in Phase 1/2 study, advancing towards combination dosing of BHV-1510 with Libtayo® in 4Q 2024 NEW HAVEN, Conn. , Nov. 12, 2024 /PRNewswire/ -- Biohaven Ltd.
- 11/12/2024
|
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
- 10/02/2024
|
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
- NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.
- 10/01/2024
|
Biohaven Announces Proposed Public Offering of Common Shares
- NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.
- 09/30/2024
|
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
- Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational treatment being developed for migraine and other pain disorders Despite recent treatment advances, migraine remains a leading cause of disability and burden, impacting 40 million people in the US and 1 billion world-wide NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.
- 09/30/2024
|
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
- The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
- 09/24/2024
|
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).
- 09/24/2024
|
Overlooked Stock: BHVN
- Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.
- 09/23/2024
|
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
- Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025.
- 09/23/2024
|
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
- Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.
- 09/23/2024
|
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
- Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of treatment.
- 09/23/2024
|
Biohaven's stock surges as treatment slows progress of neurological disorder
- Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
- 09/23/2024
|
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
- Biohaven stock jumped Monday after the company's experimental drug slowed progression in a rare disease with no approved treatments.
- 09/23/2024
|
Biohaven's genetic disease drug meets main trial goal
- Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
- 09/23/2024
|
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
- Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes. Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.
- 09/23/2024
|
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
- Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.
- 09/20/2024
|
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
- Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: The Company reported dose-dependent and rapid IgG reductions in its ongoing Phase 1 trial with its lead investigational degrader BHV-1300 No serious adverse events (SAEs) reported with BHV-1300 to date; most adverse events (AEs) were mild, deemed unrelated to study drug and resolved spontaneously Phase 1 study also completed an assessment of an optimized subcutaneous (SC) formulation of BHV-1300 that demonstrated approximately a 44% higher than expected exposure compared to the dose-equivalent intravenous formulation previously studied; this new human data further confirms feasibility of convenient self-administered SC auto-injector and the SC formulation was not associated with injection site reactions Degrader platform expected to deliver 3 INDs for new MoDE programs before year-end in addition to continued data from SAD/MAD with BHV-1300 Biohaven's beta-1 adrenergic receptor (β1AR) autoantibody targeting MoDE, BHV-1600, granted INTERACT meeting with FDA in 2H 2024 regarding development program for dilated cardiomyopathy Advancing novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indications: 5 Phase 2/3 trials with BHV-7000 underway in epilepsy and mood disorders Released positive Phase 1 data with TRPM3 antagonist BHV-2100 showing drug concentrations above EC90 target and well-tolerated profile across all doses in SAD/MAD study; advancing Phase 2 study in acute migraine and proof-of-concept (POC) study in pain in 2H 2024 Taldefgrobep alfa, a myostatin-inhibitor, progressing on track with Phase 3 topline data in spinal muscular atrophy (SMA) and Phase 2 trial initiation in obesity expected in 2H 2024 Taldefgrobep alfa has demonstrated direct effects on reducing adipose tissue (including lipid storage and mitochondrial content) independent of increases in muscle mass In a MAD study, conducted in healthy adults, taldefgrobep alfa (45 mg SC QW) produced significant reductions in total body fat while increasing total body lean mass Preclinical data released at the 2024 American Diabetes Association conference demonstrated that taldefgrobep alfa, as a monotherapy or in combination with a GLP-1 agonist, demonstrated significant reductions in fat and total body weight. Taldefgrobep alfa-treated animals showed significant increases in lean muscle, despite co-administration with a GLP-1 receptor agonist Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) selective inhibitor, BHV-8000, completed Phase 1 and confirmed biomarker target engagement with reductions in inflammatory markers and demonstrated central nervous system penetration with confirmed cerebrospinal fluid (CSF) target exposures in healthy subjects Advancing registrational programs for Parkinson's disease and prevention of Amyloid-Related Imaging Abnormalities (ARIA) following interactions with the FDA Expect interim data analysis from second ongoing Phase 3 OCD trial with troriluzole in 2H 2024; topline data from first Phase 3 OCD trial expected in 1H 2025 SCA interactions with troriluzole filing in Europe ongoing and constructive interactions in the US with the FDA New real-world evidence (RWE) protocol, incorporating feedback from the FDA, assessing 3-years of treatment with troriluzole expected to deliver topline results in 2H 2024 Biohaven antibody drug conjugate (ADC) portfolio positioned to deliver differentiated profiles and address unmet needs in oncology: BHV-1510 currently dosing cancer patients in Phase1/2 study and now advancing towards combination with Libtayo® by 4Q 2024 Portfolio of multiple advanced nonclinical BHVN ADCs demonstrate improved plasma stability and in vitro/in vivo differentiation NEW HAVEN, Conn.
- 08/08/2024
|
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
- Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone.
- 07/26/2024
|
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
- Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into the future.
- 06/28/2024
|
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
- Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
- 05/29/2024
|
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
- Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administration No SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneously No clinically significant changes in LFTs across any dose cohorts to date Highlights advances from novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indications Recently initiated a total of 5 pivotal clinical trials with selective Kv7 activator, BHV-7000, targeting focal epilepsy, idiopathic generalized epilepsy, bipolar disorder and major depressive disorder Released positive Phase 1 data with TRPM3 antagonist BHV-2100 showing drug concentrations above EC90 target and well-tolerated profile across all doses in SAD/MAD study; advancing Phase 2 study in migraine Anticipates Myostatin program topline data for Phase 3 Spinal Muscular Atrophy (SMA) study in 2H2024 Reports new preclinical data highlighting potential for taldefgrobep alfa as monotherapy and in combination with GLP-1 agonists for weight loss: Taldefgrobep alfa in combination with GLP-1 in the diet-induced obesity preclinical model showed greater reductions in body weight and fat mass, and a larger increase in lean muscle mass, compared to GLP-1 alone Taldefgrobep alfa demonstrated direct effects on fat reduction as measured by changes in adipocytes independent of increasing muscle mass Releases positive Phase 1 data with BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor, showing preliminary safety and achievement of target concentrations with reductions in inflammatory biomarkers in SAD/MAD study Key updates for BHV-8000 include favorable regulatory feedback enabling initiation of registrational programs for the prevention of ARIA associated with amyloid lowering drugs and Parkinson's disease As announced in an earlier press release today, first patient dosed with Biohaven's novel Trop-2 antibody drug conjugate (ADC), BHV-1510, in Phase 1/2 trial, as monotherapy and initiating combination with Regeneron's anti-PDL1 Libtayo®(cemiplimab-rwlc), in advanced or metastatic epithelial tumors NEW HAVEN, Conn. , May 29, 2024 /PRNewswire/ -- Biohaven Ltd.
- 05/29/2024
|
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
- -BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy -Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD-1 Libtayo® (cemiplimab-rwlc) in the Phase 1/2 clinical trial -Malignancies of epithelial tissue account for the vast majority of all cancers and the advanced or metastatic forms of these carcinomas represent an urgent unmet medical need NEW HAVEN, Conn. , May 29, 2024 /PRNewswire/ -- Biohaven Ltd.
- 05/29/2024
|
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
- Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder. Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology.
- 05/18/2024
|
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
- Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
- 05/14/2024
|
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for Biohaven Ltd. (BHVN) as it is technically in oversold territory now.
- 05/13/2024
|
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
- Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed on April 22, 2024 Completed public offering of 6,451,220 Biohaven Ltd. common shares, which included the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $41.00 per share Reported preliminary summary of data from ongoing single ascending dose (SAD) study with the lead asset from Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform, BHV-1300 FDA granted rare pediatric disease designation for the Company's anti-myostatin, taldefgrobep alfa, providing potential to receive priority review voucher (PRV) if ultimately approved for the indication of spinal muscular atrophy (SMA) Completed a "buy-back" of partial royalty and milestone considerations from Knopp for the BHV-7000 and other Kv7 pipeline programs, replacing up to low teens royalty obligations with a flat mid-single digit royalty along with certain reduced future milestones Phase 2 and 3 programs in epilepsy, major depressive disorder (MDD) and bipolar disorder initiated with selective Kv7 activator, BHV-7000 Phase 1 studies with brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibitor, BHV-8000, and Transient Receptor Potential Melastatin 3 (TRPM3) antagonist, BHV-2100, programs advancing Total of three late stage, pivotal clinical trials ongoing with taldefgrobep alfa in SMA and troriluzole in OCD 20 abstracts, including 8 oral presentations and 12 posters, featured at the American Academy of Neurology (AAN) Annual Meeting, including recognition of BHV-2100 (TRPM3 antagonist) as AAN Abstract of Distinction in the pain category; breadth of presentations highlights Biohaven's leadership in neuroscience and immunoscience as well as extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs including Kv7 ion channel modulation, MoDEs™, TYK2/JAK1 inhibition, glutamate modulation, myostatin inhibition, and TRPM3 antagonism NEW HAVEN, Conn.
- 05/09/2024
|
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
- Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.
- 05/01/2024
|
These Biotechs and IPOs Inspire Big Insider Buying
- As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.
- 04/28/2024
|
3 Biotech Stocks to Buy on the Dip: April 2024
- If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlying necessity of the ecosystem.
- 04/26/2024
|
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- NEW HAVEN, Conn. , April 22, 2024 /PRNewswire/ -- Biohaven Ltd.
- 04/22/2024
|
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
- NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.
- 04/18/2024
|
Biohaven Announces Proposed Public Offering of Common Shares
- NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.
- 04/17/2024
|
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
- Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data demonstrating rapid, robust, and selective target removal Biohaven announces it will present safety and IgG lowering data from its ongoing single ascending dose (SAD) study of BHV-1300 at the company's annual R&D day at the Yale Innovation Summit in New Haven, Connecticut on May 29, 2024 Safety, tolerability, and target engagement data showing the differentiated profile of BHV-7000 as a potential best-in-class Kv7 activator will be presented as both oral and poster presentations; the Phase 2/3 focal epilepsy program is now enrolling patients AAN Abstract of Distinction awarded to BHV-2100, which demonstrated potent reversal of pain in preclinical models and favorable initial safety and pharmacokinetic data in Phase 1 studies, highlighting the potential for TRPM3 antagonism as a novel nonopioid target to treat pain and migraine Oral and poster presentations of troriluzole as a novel glutamate modulating agent with favorable pharmacokinetics, safety, and outcomes data in the potential treatment of neurologic and neuropsychiatric disorders Biohaven announces the Data Monitoring Committee for its Phase 3 trial in obsessive-compulsive disorder convened in the second quarter to review the interim analysis and informed the Company that the study may continue Additional efficacy and safety data regarding troriluzole in spinocerebellar ataxia will also be presented in both oral and poster format Poster presentation of RESILIENT Phase 3 study design with taldefgrobep alfa in spinal muscular atrophy; study completed enrollment and topline results anticipated in the second half of 2024 Biohaven announces the FDA granted "rare pediatric disease" designation for taldefgrobep alfa thereby providing the potential to receive a priority review voucher (PRV) if ultimately approved for the indication of spinal muscular atrophy Other presentations and posters include development of the PARCOMS, a new outcome measure for Parkinson's disease clinical trials, application of machine learning in video assessment of gait, and data demonstrating a reduced risk for Parkinson's disease in patients taking anti-inflammatory agents Three oral presentations and 6 poster presentations from the Biohaven Clinical and Health Outcomes group describe the development and validation of novel scales and natural history studies in support of troriluzole and BHV-8000 development programs, the impact of immune-modulating therapy in Parkinson's disease, the burden of illness in focal epilepsy and KCNQ2-DEE (BHV-7000), and the application of AI machine learning technology to quantify patient mobility with troriluzole in spinocerebellar ataxia DENVER, CO and NEW HAVEN, Conn. , April 13, 2024 /PRNewswire/ -- Biohaven Ltd.
- 04/13/2024
|
How Biohaven's experimental obesity drug could prevent muscle loss
- Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
- 03/25/2024
|
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Also advancing potential novel treatments for rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal muscular atrophy (SMA) and IgA nephropathy.
- 02/29/2024
|
Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
- Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term health.
- 02/28/2024
|
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
- Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
- 01/25/2024
|
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
- Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
- 01/25/2024
|
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology
- Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Plus, rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal muscular atrophy and IgA nephropathy NEW HAVEN, Conn.
- 01/08/2024
|
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
- 01/02/2024
|
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
- Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous system (CNS) adverse effects associated with other anti-seizure medications (ASMs), such as somnolence and cognitive/mood disturbances. In a Phase 1 electroencephalogram (EEG) biomarker study, BHV-7000 demonstrated dose-dependent target engagement in the brain as measured by changes in EEG spectral power across all brain regions.
- 12/01/2023
|
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
- Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
- 11/16/2023
|
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.
- 11/06/2023
|
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
- Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
- 10/31/2023
|
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
- Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
- 10/19/2023
|
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
- Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
- 09/28/2023
|
Why Biohaven Stock Is Skyrocketing Today
- Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.
- 09/27/2023
|
Why Biohaven Stock Is Crashing Today
- The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency of the merits of its data on the experimental drug.
- 07/27/2023
|
2 Growth Stocks With Major Incoming Catalysts
- BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S. Food and Drug Administration accepts the company's latest new drug application.
- 06/27/2023
|
Why Biohaven Stock Caught Fire This Week
- Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appear to be optimistic about its post-buyout future.
- 06/02/2023
|
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
- At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
- 06/01/2023
|
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
- Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
- 03/30/2023
|
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
- Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
- 03/23/2023
|
Biohaven: Spun And Done - Time To Exit
- Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.
- 03/09/2023
|
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
- Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric appeared first on Investor's Business Daily.
- 02/02/2023
|
These Are the Top 10 Holdings of Paul Tudor Jones
- Paul Tudor Jones is one of the most respected names in the hedge fund industry.
- 01/10/2023
|
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
- NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.
- 01/06/2023
|
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
- Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
- 01/05/2023
|
After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
- Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
- 11/29/2022
|
Biohaven CEO on 'monumental approval' of migraine drug
- "We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.
- 11/19/2022
|
Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?
- Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
- 10/07/2022
|
Biohaven Stub May Provide An Interesting Setup For Investors
- Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price.
- 10/06/2022
|
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
- The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
- 10/06/2022
|
Why Biohaven Stock Skyrocketed Again Today
- The "new" Biohaven is enjoying plenty of attention from investors.
- 10/05/2022
|
Biohaven CEO on on Pfizer's acquisition of the company
- Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.
- 10/04/2022
|
Why Biohaven Stock Is Soaring Today
- The "old" Biohaven is gone, leaving the "new" Biohaven to rise.
- 10/04/2022
|
Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints
- Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.
- 09/30/2022
|
15 Stocks Billionaire Investors Agree It's Smart To Buy Now
- Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.
- 09/12/2022
|
Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat
- Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.
- 08/08/2022
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022.
- 08/05/2022
|
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
- Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
- 07/08/2022
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
- 06/09/2022
|
Best Health Care Stocks To Invest In 2022? 3 Names To Watch
- Here are 3 top health care stocks to watch in the stock market right now.
- 05/26/2022
|
What Stocks To Buy This Week? 4 Biotech Stocks To Know
- Should investors pay more attention to these biotech stocks?
- 05/15/2022
|
Here is why Biohaven Pharmaceuticals soared 70%
- Biohaven Pharmaceuticals Holding Company Ltd. (NYSE: BHVN) was up 70% after the company and Pfizer Inc. (NYSE: PFE) entered a definitive agreement under which Pfizer would acquire the NURTEC ODT maker.
- 05/13/2022
|
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
- Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023.
- 05/11/2022
|
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
- Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.
- 05/11/2022
|
Biohaven CEO discusses Pfizer's purchase of the company
- CNBC's Jim Cramer spoke with Biohaven CEO Vlad Coric on Tuesday's episode of "Mad Money."
- 05/10/2022
|
Pfizer deal will help expand reach of migraine pill Nurtec, Biohaven CEO says
- "We have to bring the modern day, novel therapies to those patients, and Pfizer really is the best company to build upon our work," Coric said.
- 05/10/2022
|
Why Biohaven Pharmaceutical Stock Soared Today
- An industry titan wants to buy the biotech for a whopping $11.6 billion.
- 05/10/2022
|
After Biohaven, Pfizer Likely to Remain on Acquisition Binge
- In a previous discussion on April 28, I speculated that Biogen Inc. ( BIIB , Financial) might be one of the companies interested in acquiring Biohaven Pharmaceutical Holding Co. Ltd. ( BHVN , Financial), a New Haven, Connecticut-based biopharma.
- 05/10/2022
|
Pfizer to buy rest of Biohaven for $11.6B
- Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.
- 05/10/2022
|
Biohaven Pharmaceuticals shares surge after Pfizer agrees to acquire company
- CNBC's Jim Cramer and the 'Squawk on the Street' team break down shares of Biohaven Pharmaceuticals after drug giant Pfizer agreed to acquire the company for $11.6 billion.
- 05/10/2022
|
Pfizer splashes $11.6bn of vaccine cash on Biohaven Pharmaceutical Holding
- Pfizer Inc (NYSE:PFE) has agreed a US$11.6bn offer for Biohaven Pharmaceutical Holding Co (NYSE:BHVN), which has reignited talk that more mergers and acquisitions (M&A) could be around the corner in the biotech sector. The takeover has been struck for US$148.5 of cash per share, a 78% premium to the last closing price.
- 05/10/2022
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022.
- 05/10/2022
|
Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion
- Shares of Biohaven soared following the announcement.
- 05/10/2022
|
Why Pfizer (PFE) Is Buying Biohaven Pharmaceutical (BHVN) For $11.6 Billion In Cash
- Pfizer Inc. (NYSE: PFE) announced it is buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in a deal valued at $11.6 billion in cash.
- 05/10/2022
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 05/02/2022
|
Biohaven Shares Drop Over Uncertainty About Nurtec Sales
- Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) recently shrugged off concerns about its lack of transparency on sales of its only commercial product after investors punished the company's shares.
- 04/28/2022
|
Biohaven Pharmaceutical: Recent Growth Will Continue
- Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks.
- 04/14/2022
|
Biohaven Drug Is a Long Shot, But Success Could Boost Shares
- Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) and its shareholders could be in for a pleasant surprise if the company's failed Alzheimer's drug proves effective in treating a rare disease.
- 03/22/2022
|
Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call Transcript
- Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call Transcript
- 02/25/2022
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021.
- 02/25/2022
|
Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 02/18/2022
|
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022
- NEW HAVEN, Conn., Feb. 16, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 02/16/2022
|
Biohaven (BHVN) Migraine Drug Meets Study Goals in China
- Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.
- 02/15/2022
|
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
- Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose of rimegepant.
- 02/14/2022
|
Diversify Your Portfolio With a New Psychedelic Drug ETF
- A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.
- 02/02/2022
|
Which Stocks To Buy Now? 4 Biotech Stocks To Know
- These biotech stocks could be worth watching in 2022.
- 01/07/2022
|
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
- Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
- 12/07/2021
|
Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial
- Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial. The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray and an oral med, showed "ultra-rapid pain relief" at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose in acute migraine.
- 12/06/2021
|
Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal
- Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.
- 11/10/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2021 Results - Earnings Call Transcript
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M
- Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults.
- 11/09/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -7.79% and 1.45%, respectively, for the quarter ended September 2021.
- 11/09/2021
|
Biohaven's stock slides 15% on deal with Pfizer for its migraine drug
- Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -4.29% tumbled 15.2% in premarket trading on Tuesday after it announced a deal worth up to $1.2 billion with Pfizer Inc. PFE, -0.58% to commercialize the company's migraine treatment outside of the U.S. Pfizer's stock was down 0.4% in trading before the market opened on Tuesday.
- 11/09/2021
|
Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Q3 Earnings?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 11/01/2021
|
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
- NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 10/05/2021
|
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
- Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
- 09/28/2021
|
Why Are Biohaven Shares Trading Lower On Monday?
- Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA). Verdiperstat did not differ statistically from placebo on the prespecified primary efficacy measure or the key secondary efficacy measures.
- 09/27/2021
|
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
- NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 09/09/2021
|
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
- 09/08/2021
|
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
- With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
- 08/10/2021
|
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
- Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
- 08/09/2021
|
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript
- Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021.
- 08/09/2021
|
Biohaven Pharma: Q2 Earnings Insights
- Shares of Biohaven Pharma Hldgs (NYSE:BHVN) rose 0.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 2.75% year over year to ($2.62), which beat the estimate of ($2.74).
- 08/09/2021
|
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
- NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 08/09/2021
|
Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look Out for
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 08/02/2021
|
Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race
- NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec® ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix.
- 07/29/2021
|
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202
- NEW HAVEN, Conn., July 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 07/28/2021
|
Will This Biopharma Company Continue to Crush It?
- Migraine sufferers certainly hope so.
- 07/17/2021
|
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
- Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
- 07/08/2021
|
Biohaven Pharmaceutical Stock Increased 13.56%: Why It Happened
- The stock price of Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) increased 13.56%. This is why it happened.
- 07/07/2021
|
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
- Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.
- 07/07/2021
|
Here's Why Biohaven Pharmaceutical Is Soaring Today
- Preliminary sales figures for the company's new migraine drug were much better than expected.
- 07/07/2021
|
Biohaven's stock jumps 12% after saying its migraine drug had $93 million in sales in Q2
- Shares of Biohaven Pharmaceutical Holding Co. Ltd. were up 12.1% in premarket trading on Wednesday after the company said its new migraine treatment brought in $93 million in sales in the second quarter of 2021.
- 07/07/2021
|
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
- NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.
- 07/07/2021
|
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
- TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP* receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical Holding Company Ltd.
- 06/23/2021
|
Biohaven Appoints Kishen Mehta to Board of Directors
- NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 06/17/2021
|
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
- Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other day. Enrolling will start later this year.
- 06/15/2021
|
New Strong Sell Stocks for June 14th
- CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
- 06/14/2021
|
Biohaven CEO says drug approval is 'monumental' for migraine patients
- "This is going to change the paradigm in which migraine is treated," Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec ODT received FDA approval.
- 06/08/2021
|
Biohaven CEO on 'monumental approval' of migraine drug
- "We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.
- 06/08/2021
|
Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec® ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society
- NEW HAVEN, Conn., June 3, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 06/03/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention
- The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.
- 05/28/2021
|
Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks
- The FDA has approved Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) dissolvable, Nurtec ODT (rimegepant), for preventive treatment in people who experience episodic migraines or fewer than 15 days of headaches per month. The move makes Nurtec ODT the first oral anti-CGRP drug approved for the preventive treatment of migraine and the only migraine medication approved as a dual therapy for both acute and preventive use.
- 05/28/2021
|
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment
- NEW HAVEN, Conn., May 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 05/27/2021
|
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
- MOORESVILLE, N.C., May 14, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No.
- 05/14/2021
|
Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong
- Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
- 05/11/2021
|
National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
- CHICAGO, May 11, 2021 /PRNewswire/ -- The National Headache Foundation today announced findings from a new survey, Preventing Migraine Attacks: A Current Perspective, which characterizes the experiences of people living with migraine and highlights the physical and emotional barriers to preventive treatment. The survey found half (50%) of people with migraine are extremely dissatisfied with their current ability to control their disease and report a range of emotions as a result, including frustration (39%), exhaustion (29%), stress (19%) and anxiety (15%).
- 05/11/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates (Revised)
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -44.178% and 0.05%, respectively, for the quarter ended March 2021.
- 05/11/2021
|
Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q1 2021 Results - Earnings Call Transcript
- Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Recap: Biohaven Pharma Q1 Earnings
- Shares of Biohaven Pharma Hldgs (NYSE:BHVN) fell 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 24.27% over the past year to ($2.97), which missed the estimate of ($2.82).
- 05/10/2021
|
Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
- NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 05/10/2021
|
Earnings Preview: Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Q1 Earnings Expected to Decline
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 05/03/2021
|
Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021
- NEW HAVEN, Conn., April 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 04/28/2021
|
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
- NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 04/13/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
- 04/08/2021
|
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
- MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlotte Motor Speedway.
- 04/06/2021
|
Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant
- Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding payment of $100 million. In August last year, Biohaven entered into a funding agreement with Royalty Pharma to secure up to $250 million to advance the development of zavegepant in migraine and other CGRP-mediated diseases.
- 03/29/2021
|
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
- NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/29/2021
|
Biohaven Pharmaceuticals CEO on how Nurtec migraine drug punches above its weight
- Biohaven Pharmaceuticals CEO Vlad Coric said the company's digital-first and patient-focused strategy is giving it an edge against competitors in marketing the migraine drug Nurtec.
- 03/22/2021
|
The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More
- Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.
- 03/21/2021
|
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares
- NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/15/2021
|
Biohaven Announces Proposed Public Offering Of Common Shares
- NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/15/2021
|
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
- With the trading day halfway over, the broad markets were making yet another strong push.
- 03/11/2021
|
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
- NEW HAVEN, Conn., March 11, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/11/2021
|
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
- NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/10/2021
|
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine
- NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
- 03/10/2021
|
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
- Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
- 03/02/2021
|
Biohaven: Exciting Times, Lots To Prove
- Biohaven: Exciting Times, Lots To Prove
- 03/02/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q4 2020 Results - Earnings Call Transcript
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020.
- 03/01/2021
|
Recap: Biohaven Pharmaceutical Q4 Earnings
- Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), which beat the estimate of ($2.97).
- 03/01/2021
|
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including...
- 03/01/2021
|
Biohaven Pharma's BHV-1200 Effective In Neutralizing COVID-19 Variants
- Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) hyperimmune globulin mimic developed with Biohaven's MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains found in the U.K and South Africa (B.1.1.7 and B.1.351, respectively). Preliminary lab experiments demonstrated that BHV-1200 substantially reduced viral entry into cells.
- 02/22/2021
|
Why Biohaven (BHVN) Might Surprise This Earnings Season
- Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/22/2021
|
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
- Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.
- 01/22/2021
|
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
- Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
- 01/19/2021
|
